Bardia, A., Dacosta, N. A., Gabrail, N. Y., Lemon, S., Danso, M. A., Ali, H. Y., … Traina, T. A. (2016). Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). In Journal of Clinical Oncology (Vol. 34, pp. 1088–1088). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.1088

Bardia, Aditya, Noshir Anthony Dacosta, Nashat Y. Gabrail, Stephen Lemon, Michael A. Danso, Haythem Y. Ali, Ronald Alan Fleming, et al. “Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).” In Journal of Clinical Oncology, 34:1088–1088. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.1088.

Bardia A, Dacosta NA, Gabrail NY, Lemon S, Danso MA, Ali HY, et al. Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 1088–1088.

Bardia, Aditya, et al. “Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 1088–1088. Crossref, doi:10.1200/jco.2016.34.15_suppl.1088.

Bardia A, Dacosta NA, Gabrail NY, Lemon S, Danso MA, Ali HY, Fleming RA, Kurman MR, Eisner JR, Moore WR, Gucalp A, Traina TA. Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 1088–1088.